SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-23-303981 from BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)
Date: Dec. 27, 2023 · CIK: 0001580063 · Accession: 0001193125-23-303981

AI Filing Summary & Sentiment

File numbers found in text: 333-276260

Date
December 27, 2023
Author
Not clearly detected
Form
CORRESP
Company
BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

Letter

Biora Therapeutics, Inc.

4330 La Jolla Village Drive, Suite 300

San Diego, CA 92122

(833) 727-2841

December 27, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Re:

Biora Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-276260)

To Whom it May Concern:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Biora Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to December 29, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Stewart McDowell at (415) 393-8322.

Very truly yours,
Biora Therapeutics, Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Biora Therapeutics, Inc.

4330 La Jolla Village Drive, Suite 300

 San Diego, CA 92122

(833) 727-2841

December 27, 2023

 VIA EDGAR

Securities and Exchange Commission

 Division of Corporation
Finance

 Office of Life Sciences

 100 F Street, N.E.

Washington, DC 20549

         Re:

Biora Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-276260)

 To Whom it May Concern:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Biora Therapeutics, Inc. (the “Company”)
hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to December 29, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or
our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its
obligations under the Act.

 Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson,
Dunn & Crutcher LLP by calling Stewart McDowell at (415) 393-8322.

Very truly yours,

Biora Therapeutics, Inc.

By:

/s/ Aditya P. Mohanty

Name:

Aditya P. Mohanty

Title:

Chief Executive Officer

 cc: Stewart McDowell, Gibson, Dunn & Crutcher LLP